Pharma BD Deal Intelligence
GSK plc / Stiefel Laboratories
2009 · Acquisition/Merger · $3.6B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
64
Largely worked — most objectives met.
GSK acquired Stiefel Laboratories for $3.6B, world's largest independent dermatology drug company.
Did it work? Outcome assessment
GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)
Strategic verdict
Achieved Stated Rationale
Assessment window: 5yr post-close.
Key facts
- Announced Apr 20, 2009
- Closed Jul 22, 2009
- Deal value $3.6B
- Deal type Acquisition/Merger
- Therapeutic area Dermatology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals